All patients did have significant thrombocytopenias and neutropenias, including in both tandem HSCT procedures, but these resolved with TPO-RAs and G-CSF administration giving engraftment times comparable to “regular” autologous HSCTs. The gene discussed is CSF3; the disease is neutropenia.